沙美特罗替卡松对照噻托溴铵联合沙美特罗替卡松治疗慢阻肺稳定期的观察

The Seretide Control Tiotropium Joint Seretide Treatment of Chronic Obstructive Pulmonary Disease Stability of the Observed

目的:探讨沙美特罗替卡松(舒利迭)对照噻托溴铵联合舒利迭治疗慢阻肺稳定期的观察。方法:我院采用美国Vmax6200型肺功能仪,测定最大肺活量(FVC),第一秒用力呼气量(FEV1),FEV1及FEV1/FVC。结果:治疗组FEV1、FEV1/FVC及FEV1/预计值、6MWD/m,较治疗前均有不同程度提高(P均<0.05)。而对照组上述指标前后差异无统计学意义(P>0.05)。治疗结束时两组差异有统计学意义(P<0.05)。结论:噻托溴铵联合舒利迭治疗慢阻肺稳定期疗效显著,对于并发症及生活质量的提高具有临床意义,值得推广。

Objective：The Seretide control tiotropium joint Seretide treatment of chronic obstructive pulmonary disease stability of the observed.Methods：The the U.S.Vmax6200 spirometer determination of the first second forced expiratory volume（FEV1）,forced vital capacity（FVC）,FEV1/FVC ratio and FEV1,accounting for the main indicators of expected value%.Results：Treatment group,FEV 1,FEV1/FVC ratio and FEV1 / expected value,6MWD / m,than before treatment were improved（P0.05）.Control group before and after the above-mentioned indicators were no significant differences（P0.05）.End of the treatment difference was statistically significant（P0.05）.Conclusion：Tiotropium joint Seretide treatment of chronic obstructive pulmonary disease with stable effect is significant,clinically significant complications and improved quality of life,worthy of promotion.